Skip to search formSkip to main contentSkip to account menu

E 5531

Known as: E-5531, E5531 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2001
Highly Cited
2001
ER-112022 is a novel acyclic synthetic lipid A analog that contains six symmetrically organized fatty acids on a noncarbohydrate… 
2000
2000
ABSTRACT E5531, a novel synthetic lipid A analogue, antagonizes the toxic effects of lipopolysaccharide, making it a potential… 
2000
2000
To obtain information on the effects of Ca2+ on the membrane properties of the lipid A analogue E5531, we have determined the… 
Highly Cited
1999
Highly Cited
1999
The major pathological responses to Gram‐negative bacterial sepsis are triggered by endotoxin or lipopolysaccharide. As endotoxin… 
1999
1999
ABSTRACT The purpose of this study was to determine the distribution profile of a novel endotoxin antagonist, [14C]E5531, at 1 μg… 
1999
1999
E5531 is a specific lipid A antagonist and is expected to be a drug for the treatment of septic shock. The LAL (limulus amebocyte… 
Highly Cited
1995
Highly Cited
1995
Shock due to Gram-negative bacterial sepsis is a consequence of acute inflammatory response to lipopolysaccharide (LPS) or… 
1995
1995
Lipid As from non-toxic bacteria such as Rhodobacter capsulatus and Rhodobacter sphaeroides have been shown to antagonize the…